Literature DB >> 12576814

Percutaneous management of renal pelvic urothelial tumors: long-term followup.

Mahesh C Goel1, V Mahendra, J G Roberts.   

Abstract

PURPOSE: We present the long-term outcome of percutaneous resection of renal urothelial tumor.
MATERIALS AND METHODS: A total of 24 patients underwent primary percutaneous resection of renal urothelial tumor. Patients with low stage pT0-1 disease were treated primarily with percutaneous surgery. All pelvicaliceal tumors were taken for biopsy and treated with percutaneous resection. Patients with multi-segmental pelvicaliceal system involvement, stage greater than pT1, high grade histology or additional ureteral tumors were considered for nephroureterectomy. Topical chemotherapy (mitomycin C or epirubicin) was administered via nephrostomy tube or intravesical instillation after Double-J stent (Medical Engineering Corp., New York, New York) insertion. Surveillance included upper tract cytology, nephroscopy or fiberoptic ureterorenoscopy. Long-term followup was correlated with histopathology.
RESULTS: Of the 24 cases 2 had squamous cell carcinoma, 5 had grade III transitional cell carcinoma, 15 had grade I to II transitional cell carcinoma and 2 had no tumor. Control was established with initial percutaneous resection in 18 (75%) cases and second look nephroscopy in 4. Early recurrences were detected by excretory urography (IVP) in 3 cases, small pelvic recurrences by IVP in 2, fiberoptic ureterorenoscopy in 2 and bladder tumors by flexible cystoscopy in 3 after 1 year. A total of 10 nephroscopies were performed in 5 cases, 24 flexible uretereorenoscopies in 9 and IVP in 6. Three synchronous, grade I bladder tumors were managed conventionally. All patients with high grade disease died of malignancy except one (with no further treatment) and 6 of the 15 patients with low grade noninvasive transitional cell carcinoma underwent nephroureterectomy during followup either due to progression of disease, concomitant tumor or complications. Two patients with solitary kidneys died of renal failure unrelated to malignancy. High grade tumors or tumors greater than T1 were treated with nephroureterectomy early during management. There was no perioperative mortality and 9 (60%) of the low grade cases the kidneys were preserved at a mean followup +/- SD of 64 +/- 15 months. All excised tracks from patients who underwent nephroureterectomy and the renal fossae were free of tumor on histopathological examination.
CONCLUSIONS: Percutaneous resection of transitional cell tumor should be considered primarily in patients with early stage disease excluding tumors crossing caliceal infundibula, ureteropelvic junction tumor, tumor extending over multiple calices and synchronous ureteral tumors. The long-term outcome of low grade tumors is good and they should be managed by either form of minimally invasive surgery. Nephron sparing is possible in a large percentage of low grade disease but high grade tumors should be treated with nephroureterectomy.

Entities:  

Mesh:

Year:  2003        PMID: 12576814     DOI: 10.1097/01.ju.0000050242.68745.4d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

Review 1.  Lasers in percutaneous renal procedures.

Authors:  Nadya M Cinman; Sero Andonian; Arthur D Smith
Journal:  World J Urol       Date:  2009-06-02       Impact factor: 4.226

2.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

Review 3.  Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence.

Authors:  Luca Carmignani; Roberto Bianchi; Gabriele Cozzi; Angelica Grasso; Nicola Macchione; Carlo Marenghi; Sara Melegari; Marco Rosso; Elena Tondelli; Augusto Maggioni
Journal:  Rev Urol       Date:  2013

Review 4.  Function-preserving surgery for urologic cancer.

Authors:  Kenichi Tobisu
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

Review 5.  Nephron-sparing Management of Upper Tract Urothelial Carcinoma.

Authors:  Francesca Suriano; Tommaso Brancato
Journal:  Rev Urol       Date:  2014

6.  Treatment of upper tract urothelial carcinoma: a review of surgical and adjuvant therapy.

Authors:  Kalyan C Latchamsetty; Christopher R Porter
Journal:  Rev Urol       Date:  2006

Review 7.  [Endosopic organ-sparing treatment of urothelial tumors of the upper urinary tract: indications and results].

Authors:  M Hruza; C Stock; D Teber; J J Rassweiler
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

8.  Endoscopic management of upper tract transitional cell carcinoma.

Authors:  James A Forster; Victor Palit; Anthony J Browning; Chandra Shekhar Biyani
Journal:  Indian J Urol       Date:  2010-04

9.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

10.  Endoscopic management of upper tract urothelial carcinoma.

Authors:  K Moore; J Khastgir; M Ghei
Journal:  Adv Urol       Date:  2009-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.